Related Experiment Video
Updated: Oct 2, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Strategic Exploration of Targeted Therapy for BRAF Non-V600E Mutant Lung Cancer]
Hongxia Zhang1, Jinsheng Gao2, Wei Guo3
1Department of General Practice, Liaocheng People's Hospital, Liaocheng 252000, China.
Background:
Dabrafenib+Trametinib/Dabrafenib targeted therapy has been approved for V-RAF murine sarcoma viral oncogene homolog B1 with amino acid substitution for valine at position 600 (BRAF V600E) in lung cancer patients, however, the targeted therapy strategy for lung cancer patients with BRAF non-V600E mutations has not been determined yet. This study intends to explore the efficacy of targeted therapy for BRAF non-V600E mutant lung cancer, and provide a reference for clinical treatment.
Methods:
Computer search of PubMed, Cochrane Library, Embase, Web of Science, Clinicaltrials.gov, CBM, CNKI, Wanfang database. Collect the relevant literature relevant on the targeted therapy of BRAF non-V600E mutant lung cancer, and conduct a descriptive analysis of the included literature.
Results:
There were 10 articles that met the inclusion criteria, including 3 cohort studies and 7 case reports. 18 patients with BRAF non-V600E mutant lung cancer were ineffective to vermurafenib; 1 patient obtained partial response (PR) after applying vermurafenib, 5 patients did not respond to BRAF inhibitors; 9 patients showed a potential clinical benefit rate of 34% after monotherapy with trametinib; 7 patients have different degrees of benefit from dabrafenib and trametinib on progression-free survival (PFS); 1 patient is effective to sorafenib.
Conclusions:
At present, there is no standard treatment specification for BRAF non-V600E mutation targeted therapy. The challenge lies in the heterogeneous mutation of BRAF gene. Different mutation types respond differently to targeted therapy. In addtion, real-world research evidence is scarce, so it is necessary to carry out further large-sample high-quality research to provide reference for clinical practice.
Insights
Targeted therapy for lung cancer with BRAF non-V600E mutations remains undetermined. This review found varied responses to targeted drugs, highlighting the need for further research into effective treatments for these rare mutations.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Approved targeted therapies like Dabrafenib+Trametinib are effective for BRAF V600E-mutant lung cancer.
- Optimal targeted therapy strategies for lung cancer patients with BRAF non-V600E mutations are currently undefined.
- This study addresses the critical need for understanding treatment efficacy in this patient subgroup.
Purpose of the Study:
- To explore the efficacy of targeted therapy in lung cancer patients with BRAF non-V600E mutations.
- To provide a reference for clinical treatment decisions regarding BRAF non-V600E mutant lung cancer.
- To synthesize current evidence on targeted therapy outcomes for this specific mutation profile.
Main Methods:
- Comprehensive literature search across major databases including PubMed, Embase, and Web of Science.
- Inclusion of clinical trials, cohort studies, and case reports focusing on BRAF non-V600E mutant lung cancer.
- Descriptive analysis of collected data to summarize treatment responses and outcomes.
Main Results:
- Ten studies involving 18 patients with BRAF non-V600E mutant lung cancer were analyzed.
- Varied responses observed: Ineffectiveness to vermurafenib in 18 patients, partial response in 1, and no response in 5.
- Trametinib monotherapy showed a 34% clinical benefit rate in 9 patients; dabrafenib and trametinib combination benefited 7 patients regarding progression-free survival; sorafenib was effective in 1 patient.
Conclusions:
- No standardized treatment guidelines exist for BRAF non-V600E mutation targeted therapy due to mutation heterogeneity.
- Different BRAF non-V600E mutation subtypes exhibit distinct responses to targeted agents.
- Scarcity of real-world evidence necessitates large-scale, high-quality research to guide clinical practice.
More Related Videos
08:18Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...